1601482-72-7

Basic information

• Product Name: tert-butyl ((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)tetrahydro-2H-pyran-3-yl)carbamate
• Synonyms: tert-butyl ((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)tetrahydro-2H-pyran-3-yl)carbamate
• CAS NO: 1601482-72-7
• Molecular Weight: 424.488
• Mol File: 1601482-72-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl ((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)tetrahydro-2H-pyran-3-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl ((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)tetrahydro-2H-pyran-3-yl)carbamate(1601482-72-7)
• EPA Substance Registry System: tert-butyl ((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)tetrahydro-2H-pyran-3-yl)carbamate(1601482-72-7)

Safety Data

• Hazardous Substances Data: 1601482-72-7(Hazardous Substances Data)

Upstream product

• 951127-26-7 1-(2,5-difluorophenyl)-2-nitroethanol 
• 2646-90-4 2,5-difluorobenzaldehyde 
• 951127-25-6 N-[(2R,3S)-2-(2,5-difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester 
• 1601482-74-9 hexahydro-1H-furo[3,4-c]pyrrol-5-ium 4-methylbenzenesulfonate 
• 951127-28-9 6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran 
• 951127-27-8 1-(2,5-difluorophenyl)-2-nitroethanone 

Downstream Products

• 1601479-76-8 (2R,3 S,5R)-2-(2,5-difluorophenyl)-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)tetrahydro-2H-pyran-3-amine 

Relevant articles and documents

2-PHENYL-5-HETEROCYCLYL-TETRAHYDRO-2H-PYRAN-3-AMINE COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND ITS ASSOCIATED DISORDERS

The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of diabetes mellitus (DM), obesity and other metabolic disorders. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.